BioWorld

Jan. 4, 2007

Cytokinetics Forms $725M Heart Disease Alliance With Amgen

Providing leverage for a small-molecule program targeted at heart failure, Cytokinetics Inc. is collaborating with Amgen Inc. in a deal potentially worth $725 million. (BioWorld Today) Read More

Genentech Paying Exelixis $40M In MEK Inhibitor Deal

Cloned Cows Safe, Knockouts Healthy, But Not In Supermarket

FivePrime Signs Discovery Deal With Centocor; $15M Up Front

VaxGen Future Unclear With Additional $51M Celltrion Sale

FDA Signs Off On Poniard's Phase III Picoplatin Protocol

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 16, 2025.

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

BioWorld

During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...

23andme founder-led group outbids Regeneron for company

BioWorld

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...

Elevidys’ second liver death hits Sarepta, sends DMD ripples

BioWorld

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...